On Ozempic, Wegovy, Mounjaro or Zepbound? Steady is the daily companion that protects your muscle, reads your cycle, and makes sense of the side effects no one warned you about.
A June 2026 meta-analysis of 28 trials puts tirzepatide vs semaglutide head to head. Tirzepatide won on weight, but the best drug is the one you stay on.
Nausea on day three.
A plateau on month three.
Hair in the shower on month six.
Every other tracker treats a GLP-1 like a diet app. You're doing something far more specific, and far harder. Steady was built for that.
Dose. Protein. Water. Fibre. One glance, every day.
Every day you’ve logged. In one unbroken line.
The weight curve. The weekly score. A picture a doctor can read.
A GLP-1-aware assistant that reads your day before it answers.
A real weight curve, not a scale-day snapshot. A weekly scorecard on protein, fibre and hydration. A symptom heatmap that shows when nausea hits, not just that it did. At your next appointment, hand over a month of signal, not a guess.
Appetite drops fast on a GLP-1, and so does muscle, if you’re not careful. Steady targets 120g of protein a day and tells you what to eat next. Not what you ate.
Nausea hits harder in the luteal phase. Cravings spike before your period. Steady reads your cycle and changes its advice, so you stop blaming yourself for biology.
Nausea, fatigue, constipation, vomiting, heartburn, mood changes and eight more. Log severity in seconds. At your next appointment, hand your doctor a real picture of your month.
Your dose, your cycle, your weight, they stay between you and Steady. Not sold. Not shared with advertisers. Not used to train AI models.
Not a banner, not a sponsored coach reply, not a partner deal. The subscription pays for the app. That is the whole contract.
No red faces. No “guilty pleasure” categories. No streak you'll dread breaking. Steady reads your day; it doesn't grade it.
If you're losing weight too fast, the app says so. If your cycle is in luteal week, it changes its tone. The drug is doing the hard part; we don't add weight to the climb.
Built on peer-reviewed GLP-1 research, including what the studies leave out about women, cycles, and the months after the scale stops moving.
